# Surgery Partners Inc. (SGRY) fundamentals

Data as of 2026-11-04. NASDAQ, United States. Sector: Healthcare / Health Care Providers. Price $23.13, market value $3.0 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Surgery Partners Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **PEG: 2.03**. A PEG of 2.03 means the P/E is high relative to expected earnings growth; the price already assumes a lot.
- **Price / sales: 0.9×**. Each dollar of revenue is priced at 0.9×, a low multiple typical of thin-margin businesses or out-of-favour stocks.
- **Price / book: 1.8×**. The shares trade at 1.8× book value; book value is a meaningful part of the valuation.
- **EV / EBITDA: 11.5×**. Enterprise value is 11.5× operating earnings before depreciation, the multiple that ignores how the company is financed.
- **Free-cash-flow yield: 6.3%** (5-yr avg 5.3%). Free cash flow equals 6.3% of the market value, in line with its five-year average of 5.3%. Above 5% is generally attractive.

## Profitability
- **Operating margin: 11.4%**. 11.4% of revenue is left after running the business.
- **Net margin: -2.4%**. The company reported a net loss over the last twelve months.
- **Return on equity: -4.5%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 5.8%**. Return on all capital, debt included, is 5.8%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -1.1%**. Each dollar of assets produces -1.1% of profit.

## Growth
- **Revenue growth (1 yr): 6.2%** (3-yr 9.2%/yr, 5-yr 12.2%/yr). Revenue grew 6.2% over the last year, against 12.2% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): 54.1%**. Earnings per share rose 54.1%, faster than revenue, so margins expanded or the share count shrank.
- **Free-cash-flow growth (3 yr): 35.7%/yr**. Free cash flow has compounded at 35.7% a year over three years.

## Financial health
- **Debt to equity: 2.18**. Debt is 2.18 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Net debt / EBITDA: 6.2×**. It would take 6.2 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Current ratio: 1.87** (quick 1.87). Current assets cover the next year's liabilities 1.87 times.
- **Piotroski F-score: 5/9**. 5 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. Surgery Partners Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (5 analysts). 5 analysts cover Surgery Partners Inc.; the consensus is buy, with an average price target of $21.70 (-6% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 6.6%** (YTD 49.7%, 3-mo 47.8%). The shares are up 6.6% over twelve months including dividends.
- **From 52-week high: -1.0%** (102.7% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 85**. An RSI of 85 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.83** (volatility 70%). Beta of 0.83 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SGRY · Page: https://foliofundamentals.com/stocks/sgry

Not investment advice.